GPX2 and glioblastoma: Since the antioxidant response seems to be crucial in the resistance against CLytA-DAAO-induced cell death, in the current work, a pilot study has been initiated to evaluate the CAT, NFE2L2 and GPX2 expression in biopsies from patients with pancreatic carcinoma, colorectal carcinoma, and glioblastoma (Figure 10).